Drug recall · July 14, 2021
Topotecan Injection 4 mg/4mL recall
Why: Presence of Particulate Matter: Complaint received of a glass particle observed inside the vial. The vial was returned to Teva for further analysis where two other particulates were found and identified as one (1) grey silicone particle and one (1) translucent, colorless cotton fiber.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Topotecan Injection 4 mg/4mL (1 mg/mL), Single-Dose vial, Teva Pharmaceuticals USA, Inc. North Whales, PA 19454, Carton NDC# 0703-4714-01, Vial NDC# 0703-4714-71
- Lots / codes
Lot # 31328962B, exp. date 04/2022
- Quantity
- 10,425 vials
- Company
- Teva Pharmaceuticals USA, Parsippany, NJ
- Distribution
- Distributed Nationwide in the USA
- Initiated
- June 18, 2021 · Voluntary: Firm initiated
- Classified
- July 15, 2021
- Reported
- July 14, 2021
- Ended
- April 4, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Topotecan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.